Tislelizumab plus chemotherapy vs chemotherapy alone as first-line treatment for advanced squamous non–small-cell lung cancer: a phase 3 randomized clinical trial
J Wang, S Lu, X Yu, Y Hu, Y Sun, Z Wang… - JAMA …, 2021 - jamanetwork.com
… as first-line treatment for patients with advanced sq-NSCLC. … 3 clinical trial was conducted
at 46 sites in China between July 2018 and June 2019 and included patients with treatment-…
at 46 sites in China between July 2018 and June 2019 and included patients with treatment-…
… for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial
A Sezer, S Kilickap, M Gümüş, I Bondarenko… - The Lancet, 2021 - thelancet.com
… in clinical trials, making the present study more reflective of real-world clinical practice. …
of platinum-doublet chemotherapy in the first-line treatment of patients with advanced non-small-…
of platinum-doublet chemotherapy in the first-line treatment of patients with advanced non-small-…
… with or without tremelimumab vs standard chemotherapy in first-line treatment of metastatic non–small cell lung cancer: the MYSTIC phase 3 randomized clinical trial
NA Rizvi, BC Cho, N Reinmuth, KH Lee, A Luft… - JAMA …, 2020 - jamanetwork.com
… chemotherapy as a first-line treatment for patients with metastatic non–small cell lung cancer.
… 3 randomized clinical trial (MYSTIC) was conducted at 203 cancer treatment centers in 17 …
… 3 randomized clinical trial (MYSTIC) was conducted at 203 cancer treatment centers in 17 …
… or pembrolizumab plus chemotherapy vs chemotherapy alone for patients with first-line, advanced gastric cancer: the KEYNOTE-062 phase 3 randomized clinical trial
… that reported in prior first-line global studies in patients with G… be necessary in future clinical
studies evaluating the delayed … for treatment with pembrolizumab in an earlier line of therapy…
studies evaluating the delayed … for treatment with pembrolizumab in an earlier line of therapy…
[HTML][HTML] A randomized, placebo-controlled trial of pembrolizumab plus chemotherapy in patients with metastatic squamous NSCLC: protocol-specified final analysis of …
L Paz-Ares, D Vicente, A Tafreshi, A Robinson… - Journal of Thoracic …, 2020 - Elsevier
… To characterize the treatment effect of pembrolizumab on the next line of therapy, we …
objective tumor progression on next-line treatment or death, whichever occurred first. In addition, to …
objective tumor progression on next-line treatment or death, whichever occurred first. In addition, to …
… on survival and progression-free survival in patients with advanced or metastatic esophageal squamous cell carcinoma: the ESCORT-1st randomized clinical trial
…, L Chen, L Bai, J Zhang, ESCORT-1st Investigators - Jama, 2021 - jamanetwork.com
… 2 and the current recommended standard first-line therapy for this advanced or metastatic
disease … clinical studies. Therefore, novel drugs and strategies are required to improve clinical …
disease … clinical studies. Therefore, novel drugs and strategies are required to improve clinical …
First-line immunotherapy for non–small-cell lung cancer
… Looking forward, there are several new agents being evaluated in randomized clinical
trials in the first line, which could soon be integrated into our clinical armamentarium. …
trials in the first line, which could soon be integrated into our clinical armamentarium. …
Phase 3 randomized, open-label, multicenter study of tremelimumab (T) and durvalumab (D) as first-line therapy in patients (pts) with unresectable hepatocellular …
GK Abou-Alfa, SL Chan, M Kudo, G Lau, RK Kelley… - 2022 - ascopubs.org
… Conclusions: HIMALAYA was the first large phase 3 trial with a diverse, representative
uHCC … , novel, first-line standard of care systemic therapy for uHCC. Clinical trial information: …
uHCC … , novel, first-line standard of care systemic therapy for uHCC. Clinical trial information: …
Innate immunity: the first line of defense against SARS-CoV-2
MS Diamond, TD Kanneganti - Nature immunology, 2022 - nature.com
… , many treatment strategies have been investigated. The rate of clinical trials for COVID-19
has … Clinical trials of these treatments have led to FDA approval of remdesivir and EUA for the …
has … Clinical trials of these treatments have led to FDA approval of remdesivir and EUA for the …
Second-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer (ABC-06): a phase 3, open-label, randomised, controlled trial
A Lamarca, DH Palmer, HS Wasan, PJ Ross… - The Lancet …, 2021 - thelancet.com
… benefits and risks from second-line FOLFOX chemotherapy in advanced biliary tract … line
treatment for advanced biliary tract cancer and the reference regimen for further clinical trials…
treatment for advanced biliary tract cancer and the reference regimen for further clinical trials…
相关搜索
- cell lung cancer first line treatment
- randomized clinical trial first line treatment
- nonsquamous nsclc first line treatment
- pd l1 first line treatment
- tislelizumab in combination first line treatment
- first line therapy tremelimumab in combination
- apatinib and chemotherapy first line treatment
- first line therapy unresectable hepatocellular carcinoma
- first line therapy pemetrexed and carboplatin
- himalaya study first line treatment
- first line immunotherapy
- second line therapy
- cemiplimab monotherapy for first line treatment
- standard chemotherapy in first line treatment
- tislelizumab plus chemotherapy first line treatment
- phase 2 study first line treatment